Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
5.29 ^USD	+1.54%		-8.48%	-41.16%

14/05	Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	CI
07/05	Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	CI

Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022 and 2023

November 03, 2022 at 03:30 pm IST

Aurinia Pharmaceuticals Inc. provided revenue guidance for the year 2022 and 2023. Given these current market dynamics, company is adjusting net revenue guidance to $100 million - $105 million from sales of LUPKYNIS for 2022. Company is also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million.

Latest news about Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	14/05	CI
Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	07/05	CI
Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	02/05	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	30/04	CI
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	21/03	CI
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	08/03	MT
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	08/03	MT
HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	22/02	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	16/02	MT
Sector Update: Health Care Stocks Higher Late Afternoon	16/02	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	16/02	MT
Sector Update: Health Care	16/02	MT
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	15/02	MT
Transcript : Aurinia Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 15, 2024	15/02
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	15/02	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	15/02	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	15/02	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	15/02	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	15/02	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	15/02	CI

Chart Aurinia Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Sector

Biotechnology & Medical Research

Calendar

14/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aurinia Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.29 USD

Average target price

10.14 USD

Spread / Average Target

+91.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AURINIA PHARMACEUTICALS INC.	-41.16%	74Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	11TCr
BIONTECH SE	-10.84%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.17TCr

Bio Therapeutic Drugs